Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries

INTRODUCTION: The current use of lipid lowering therapies and the eligibility for proprotein convertase subtilisin/kexin-9 (PCSK9) inhibitors of patients surviving a myocardial infarction (MI) is poorly known. METHODS: Using the data from two contemporary, nationwide, prospective, real-world registr...

Descripción completa

Detalles Bibliográficos
Autores principales: Colivicchi, Furio, Massimo Gulizia, Michele, Arca, Marcello, Luigi Temporelli, Pier, Gonzini, Lucio, Venturelli, Vanessa, Morici, Nuccia, Indolfi, Ciro, Gabrielli, Domenico, De Luca, Leonardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961602/
https://www.ncbi.nlm.nih.gov/pubmed/31969932
http://dx.doi.org/10.1155/2020/3856242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961602/
https://www.ncbi.nlm.nih.gov/pubmed/31969932
http://dx.doi.org/10.1155/2020/3856242

Ejemplares similares